characteristics.text: ERC000011
characteristics.characteristic: ENA-CHECKLIST
characteristics.text: 2023-09-29T00:23:06Z
characteristics.characteristic: ENA-FIRST-PUBLIC
characteristics.text: 2023-09-29T00:23:06Z
characteristics.characteristic: ENA-LAST-UPDATE
characteristics.text: SAMEA113563475
characteristics.characteristic: External Id
characteristics.text: ONTARIO INSTITUTE FOR CANCER RESEARCH
characteristics.characteristic: INSDC center name
characteristics.text: 2023-09-29T00:23:06Z
characteristics.characteristic: INSDC first public
characteristics.text: 2023-09-29T00:23:06Z
characteristics.characteristic: INSDC last update
characteristics.text: public
characteristics.characteristic: INSDC status
characteristics.text: ERS15559623
characteristics.characteristic: SRA accession
characteristics.text: E-MTAB-12859:Sample 1 (729_G5_a)
characteristics.characteristic: Submitter Id
characteristics.text: ArrayExpress
characteristics.characteristic: broker name
characteristics.text: G729
characteristics.characteristic: cell_line
characteristics.text: human
characteristics.characteristic: common name
characteristics.text: Protocols: GBM cells for functional experiments were obtained following informed consent from patients. Experiments were in accordance with the Research Ethics Board at The Hospital for Sick Children (Toronto, Canada). Access to pathological data was obtained from the institutional review boards. GBM stem cell lines (G797, G729, G411), which were established from mesenchymal GBMs, were cultured using previously established protocols (85) including serum-free NS cell self-renewal media (NS media) consisting of Neurocult NS-A Basal media, supplemented with 2 mmol/L L-glutamine, hormone mix (in house equivalent to N2), B27 supplements, 75 mg/mL BSA, 2 mg/mL Heparin, 10 ng/mL basic FGF and 10 ng/mL human EGF. GBM cell lines were grown adherently on culture plates coated with poly-L-ornithine and laminin and maintained in 37°C tissue culture incubator with 5% CO2. All cell lines were regularly checked for mycoplasma infections by DAPI staining. RNA-seq data was generated in the patient-derived GBM cell line G729 with shRNA targeting GJB2, SCN9A, or non-targeting (NT) shRNA controls, as described above. Total RNA was collected 4 days post lentiviral shRNA transduction using RNeasy Plus Mini Kit (Qiagen #74134). Lentiviral transduction and RNA extraction were performed in triplicates. RNA integrity number (RIN) was determined using Agilent Bioanalyzer. All samples had RIN > 9.8. Library preparation was performed using NEBNext Ultra II Directional polyA mRNA Library Prep Kit.
characteristics.characteristic: description
characteristics.text: brain glioblastoma
characteristics.characteristic: disease
characteristics.text: wild type genotype
characteristics.characteristic: genotype
characteristics.text: not applicable
characteristics.characteristic: isolate
characteristics.text: Homo sapiens
characteristics.characteristic: organism
characteristics.text: Homo sapiens
characteristics.characteristic: organism
characteristics.text: brain
characteristics.characteristic: organism part
characteristics.text: Homo sapiens
characteristics.characteristic: scientific_name
characteristics.text: Sample 1 (729_G5_a)
characteristics.characteristic: title